Company preview: upcoming American Academy of Ophthalmology (AAO) 2023 meeting presentations and data releases

News
Article

Several companies including Kiora Pharmaceuticals, Adverum Biotechnologies and Aviceda Therapeutics, will share data at the 2023 meeting in San Francisco, California

Audience members sit in front of a stage at a conference. Image credit: Image credit: ©Dziurek – stock.adobe.com

The team from Ophthalmology Times will be in attendance at the meeting to bring you the latest news and data from this event. Image credit: ©Dziurek – stock.adobe.com

As attendees, presenters and press gear up for the annual American Academy of Ophthalmology meeting in San Francisco, companies from around the globe are hinting at the data and technology that will be on display.

Among the companies who will be present is Kiora Pharmaceuticals. They will present their topline results from the ABACUS study, which is a Phase 1b study evaluating KIO-301 for the treatment of retinitis pigmentosa. The results are a part of retinal subspecialty day and were submitted and accepted as a late breaking abstract. The presentation is titled "Intravitreal Injection of 'Photoswitch' Molecule (KIO-301) Improves Visual Function in Late-Stage Retinitis Pigmentosa (RP) Patients” and will be given by Russell N. Van Gelder, MD, PhD, chair of the Department of Ophthalmology, University of Washington School of Medicine on November 4, 2023, at 9:15 am PT.1

Adverum Biotechnologies will present OPTIC four-year Ixo-vec aflibercept protein expression data and three-year extension efficacy and safety data at the AAO meeting. This follows the company’s recent release of phase 2 LUNA data, which evaluated Ixo-vec for the treatment of wet age-related macular degeneration (wet AMD).2

Aviceda Therapeutics will also share positive data from the SIGLEC trial during the Eyecelerator session at the meeting. This follows their recent announcement of full enrollment for all 4 cohorts of part 1 at the Retina Society meeting.3

AEYE Health will be on site to share more about their AI-based diabetic retinopathy screening solution. In a press release, the company shared that their screening system has significantly reduced its processing time to under 5 seconds.4

Bausch + Lomb will showcase their surgical solutions at the meeting. The company will be located at Booth 521 in the exhibit hall and will have their latest surgical equipment on site for ophthalmic surgeons to learn more about the ergonomic designs.5

Our colleagues from Ophthalmology Times will also be in attendance at the meeting to bring you the latest news and data from this event.

References:
  1. Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa. Kiora Pharmaceuticals. September 14, 2023. Accessed October 23, 2023. https://www.biospace.com/article/releases/kiora-pharmaceuticals-to-present-topline-results-from-the-abacus-study-at-american-academy-ophthalmology-aao-phase-1b-study-evaluating-kio-301-in-retinitis-pigmentosa/
  2. Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial. Adverum Biotechnologies, Inc. September 26, 2023. Accessed October 23, 2023.https://www.biospace.com/article/releases/adverum-biotechnologies-announces-positive-aflibercept-protein-level-data-from-the-luna-phase-2-trial/
  3. Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent. Aviceda Therapeutics. October 23, 2023. Accessed October 23, 2023. https://www.biospace.com/article/releases/aviceda-completes-enrollment-in-part-1-of-the-siglec-phase-2-3-u-s-clinical-trial-initiation-of-part-2-imminent/
  4. AEYE Health Makes Its One-Image-Per-Eye Diabetic Eye Exam Even Faster by Cutting Processing Time to Under 5 Seconds. AEYE Health. October 3, 2023. Accessed October 23, 2023. https://www.prnewswire.com/news-releases/aeye-health-makes-its-one-image-per-eye-diabetic-eye-exam-even-faster-by-cutting-processing-time-to-under-5-seconds-301945846.html
  5. Rethink Ophthalmic. Bausch + Lomb. Accessed October 23, 2023. https://www.bauschsurgical.com/AAO
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.